Biogen's Q4 2024 earnings showed slight revenue growth but Wall Street remains unimpressed due to weak guidance and declining key drug franchises. Leqembi's commercial performance is disappointing ...

Biogen Pharmachem Industries Ltd share price was down by -0.93% from the previous closing price of ₹1.07. Who are peers of Biogen Pharmachem Industries Ltd? The peers of Biogen Pharmachem ...

Biogen has finalised a $900 million payment to settle a whistleblower lawsuit claiming that it paid kickbacks to US doctors to prescribe its multiple sclerosis drugs.

Eisai and Biogen have completed their rolling biologics license application in the US for a subcutaneous formulation of Alzheimer's disease therapy Leqembi previously delayed by the FDA on ...

The World EPA organisers have curated an exceptional programme featuring thought-provoking presentations and dynamic panel ...

After hours: February 14 at 7:14:20 PM EST ...

Pre-market: 5:02:58 am GMT-5 ...

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world ...